Evidence map›Paper›PMID 42120180›Full record

ArticleJournal for immunotherapy of cancer2026

CXCL16-driven CD4

Yunyi Zhou, Ping Chen, Zhixue Wang, Liming Gui, Zhengheng Zheng, Wei-Qiang Gao, Bin Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yunyi Zhou *Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Ping Chen *Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Zhixue WangShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Liming GuiShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Zhengheng ZhengShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Wei-Qiang GaoSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Bin MaShanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China bin.ma@outlook.com.ORCID http://orcid.org/0000-0001-5744-9667

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor histocompatibility complex class I (MHC)-I loss is a prevalent mechanism for immune evasion and resistance to immunotherapy. However, how MHC-I loss shapes the tumor microenvironment and influences immune cell interactions, ultimately affecting tumor growth, remains largely unknown.

methodsWe established

resultsMHC-I loss promoted tumor growth in MC38, AKR, and LLC1 models, but unexpectedly suppressed Hepa1-6 and orthotopic

conclusionCXCL16-driven CD4

Indexed as

Carcinoma, HepatocellularCD4-Positive T-LymphocytesChemokine CXCL16Histocompatibility Antigens Class IImmunologic SurveillanceLiver NeoplasmsAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLMice, KnockoutTumor MicroenvironmentChemokine CXCL16Cxcl16 protein, mouseHistocompatibility Antigens Class IEscape/evasionMajor histocompatibility complex - MHCSolid tumorT cellTumor microenvironment - TME

Identifiers

PMID42120180
PMCPMC13182305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.